Carlyle Group Adjusts Soleno Therapeutics Stake

Ticker: SLNO · Form: SC 13D/A · Filed: 2024-10-10T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 13d-amendment, ownership-change

TL;DR

Carlyle Group filed an update on their Soleno Therapeutics holdings. Watch for potential moves.

AI Summary

On October 10, 2024, Carlyle Group Inc. and its affiliates filed an SC 13D/A amendment regarding their holdings in Soleno Therapeutics Inc. The filing indicates a change in beneficial ownership, with Carlyle Group Inc. now listed as a filer alongside several of its associated entities, including Abingworth Bioventures VII LP and Carlyle Genesis UK LLC. This amendment likely reflects adjustments to their investment strategy or reporting requirements concerning Soleno Therapeutics.

Why It Matters

This filing signals a potential shift in significant ownership for Soleno Therapeutics, which could impact its stock price and strategic direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership by large investment firms can indicate strategic shifts or potential future actions that may affect stock price.

Key Players & Entities

FAQ

What specific changes in beneficial ownership are detailed in this SC 13D/A filing for Soleno Therapeutics?

The filing is an amendment (SC 13D/A) and indicates a change in beneficial ownership by Carlyle Group Inc. and its affiliates, but the exact percentage or number of shares changing hands is not detailed in the provided header information.

When was this SC 13D/A filing submitted to the SEC?

The filing was submitted on October 10, 2024.

Who are the primary entities involved in this filing besides Soleno Therapeutics Inc.?

The primary filing entity is Carlyle Group Inc., along with its group members such as Abingworth Bioventures VII LP, Abingworth LLP, Carlyle Genesis UK LLC, and others.

What is the business address of Soleno Therapeutics Inc.?

The business address for Soleno Therapeutics Inc. is 100 Marine Parkway, Suite 400, Redwood City, CA 94065.

What was Soleno Therapeutics Inc. formerly known as?

Soleno Therapeutics Inc. was formerly known as Capnia, Inc., with a name change date of February 19, 2010.

Filing Stats: 2,712 words · 11 min read · ~9 pages · Grade level 10.1 · Accepted 2024-10-10 16:30:57

Key Financial Figures

Filing Documents

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 40,108,265 shares of Common Stock, which includes (i) 38,871,594 shares of Common Stock outstanding as of August 2, 2024, as disclosed in the Issuers quarterly report on Form 10-Q filed on August 7, 2024, (ii) 22,913 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof and (iii) 1,213,758 shares of Common Stock underlying the Prefunded Warrants, all of which are currently exercisable. Reporting Person Amount beneficially owned Percent of class Sole power to vote or to direct the vote Shared power to vote or to direct the vote Sole power to dispose or to direct the disposition Shared power to dispose or to direct the disposition The Carlyle Group Inc. 3,251,078 8.1 % 0 3,251,078 0 3,251,078 Carlyle Holdings I GP Inc. 3,251,078 8.1 % 0 3,251,078 0 3,251,078 Carlyle Holdings I GP Sub L.L.C. 3,251,078 8.1 % 0 3,251,078 0 3,251,078 Carlyle Holdings I L.P. 3,251,078 8.1 % 0 3,251,078 0 3,251,078 CG Subsidiary Holdings L.L.C. 3,251,078 8.1 % 0 3,251,078 0 3,251,078 TC Group, L.L.C. 3,251,078 8.1 % 0 3,251,078 0 3,251,078 Carlyle Investment Management L.L.C. 3,251,078 8.1 % 0 3,251,078 0 3,251,078 Carlyle Genesis UK LLC 3,251,078 8.1 % 0 3,251,078 0 3,251,078 Abingworth LLP 3,251,078 8.1 % 0 3

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : October 10, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings I GP Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I L.P. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group, L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CUSIP No. 834203200 13D Page 15 of 15 pages Carlyle Investment Management L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Abingworth LLP By: /s/ John Heard Name: John Heard Title: Authorized Signatory Abingworth Bioventures VII LP By: /s/ John Heard Name: John Heard Title: Authorized Signatory

View on Read The Filing